Table 2.
Associations between vedolizumab serum trough concentrations and variable treatment endpoints, median (interquartile range)
|
Median vedolizumab serum trough concentrations (µg/mL)
|
No clinical remission
|
Clinical remission
|
P value
|
No endoscopic improvement
|
Endoscopic improvement
|
P value
|
No histologic remission
|
Histologic remission
|
P value
|
| Week 01 | 14.0 (6.4-22.2) | 15.7 (11.5-20.1) | 0.47 | 13.9 (10.4-22.2) | 15.9 (11.5-20.1) | 0.69 | 16.0 (11.1-21.7) | 15.5 (11.2-19) | 0.44 |
| Week 48 | 9.2 (5.4-21.7) | 16.3 (12.5-22.4) | 0.04 | 12.3 (8.1-21.9) | 17.7 (13.5-21.1) | 0.09 | 15.4 (9.8-21.9) | 17 (12.6-21.0) | 0.78 |
| 2 years2 | 12.4 (7.0-15.0) |
17.7 (12.6-22.5) |
0.02 |
1
Vedolizumab serum trough concentrations at week 0 vs remission rates at week 48.
2
Vedolizumab serum trough concentrations at week 48 vs clinical remission at 2 years.